Related Experiment Videos
Prognostic significance of plasma cell morphology in multiple myeloma
Abstract:
The effect of bone marrow plasma cell morphology at diagnosis on survival time was evaluated in 139 patients with multiple myeloma. According to the morphological classification scheme the patients were categorized as mature (30 patients), immature (76 patients) or plasmablastic (33 patients). The plasmablastic group had an estimated median survival (Kaplan-Meier method) of 10.9 months, compared with 32.2 months for immature and 60 months for mature types (P = 0.0000). The prognostic value of a morphologic classification in multiple myeloma was further demonstrated by means of a multivariate linear regression analysis of survival data. Expected survival was calculated using clinical features and morphologic subtypes. The estimated survival time for plasmablastic myeloma was shorter by 51.4 months and for immature myeloma patients by 35 months, compared with mature myeloma patients with similar clinical characteristics. Plasma cell morphology at diagnosis is an important predictor of survival duration in patients with multiple myeloma.
Insights
Plasma cell morphology in multiple myeloma diagnosis significantly impacts survival. Plasmablastic types show shorter survival, while mature types have longer survival, aiding prognosis.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Multiple myeloma is a hematologic malignancy characterized by plasma cell proliferation.
- Prognostic factors are crucial for guiding treatment and predicting patient outcomes.
Purpose of the Study:
- To evaluate the effect of bone marrow plasma cell morphology at diagnosis on survival time in multiple myeloma patients.
- To determine if plasma cell morphology is an independent predictor of survival.
Main Methods:
- Morphological classification of bone marrow plasma cells into mature, immature, and plasmablastic subtypes.
- Survival analysis using the Kaplan-Meier method.
- Multivariate linear regression analysis incorporating clinical features and morphological subtypes.
Main Results:
- Plasmablastic myeloma showed a median survival of 10.9 months.
- Immature myeloma had a median survival of 32.2 months.
- Mature myeloma exhibited the longest median survival at 60 months (P = 0.0000).
- Plasmablastic and immature subtypes were associated with significantly shorter survival compared to mature types, even after adjusting for clinical factors.
Conclusions:
- Plasma cell morphology at diagnosis is a significant and independent predictor of survival duration in multiple myeloma.
- Morphological classification provides valuable prognostic information for patients with multiple myeloma.